Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update for 3/23/2020

3/23/2020

 
Remdesivir
  • Gilead ended a compassionate use program for remdesivir on 3/22/2020 due to overwhelming demand for the drug. Compassionate use may still be requested for pregnant women and children under 18 years of age with confirmed COVID-19 and severe manifestations of disease. The request must be made through the web site. The online form requires information to justify the need for remdesivir.
  • Gilead is working with the FDA to implement an expanded access program to provide access to the drug for patients unable to participate in a clinical trial.  The goal is to accelerate access to remdesivir for severely ill patients and enable the collection of data from all participating patients. 
  • Gilead has a special expanded use program for patients treated at U.S. military hospitals though NCT04302766.
Delays in Trial Recruitment

The COVID-19 pandemic is causing a delay in recruitment and completion of investigational drug clinical trials. Several pharmaceutical companies have announced delays due to the virus. In some cases new trials are being postponed and in other cases existing trials are being halted or arrangements made to provide study medication to patients. The pool of patients and those willing to volunteer is smaller while the pandemic impacts the health and movement of patients. Healthcare providers and healthcare facilities also have less time and space to use for trials.
 
Chloroquine and Hydroxychloroquine
  • Bayer, Novartis and Teva are donating millions of doses of chloroquine and hydroxychloroquine for clinical trials and treatment.
  • The FDA wants to see the drugs evaluated in a large clinical trial, before their use becomes a standard practice. 
  • Teva, Novartis and Mylan have announced plans to increase production of the drugs.
  • Bayer, Zydus Pharmaceuticals, Prasco Labs, Rising Pharmaceuticals and Sun Pharmaceuticals also make the drugs.
  • Chloroquine went into shortage on March 9
  • Hydroxychloroquine went on shortage on March 19
  • The shortage in hydroxychloroquine and chloroquine was due to a large increase in purchases in March
Interleukin 6 (IL-6) Monoclonal Antibodies
  • Three Interleukin 6 (IL-6) monoclonal antibodies are being evaluated to reduce lung damage from severe COVID-19 pneumonia.
    • Tocilizumab (Actemra, Roche) is being evaluated in a Chinese trial. Roche and BARDA will compare the effect of tocilizumab to placebo in the Phase III COVACTA trial.
    • Sarilumab (Kevzara, Regeneron, Sanofi) is being investigated by Regeneron and Sanofi in a Phase II/III adaptive trial. The initial phase of the trial will determine the dose to be used in the larger portion of the trial.
    • Siltuximab (Sylvant, EUSA Pharma) is being evaluated in the Italian SISCO trial sponsored by EUSA.
  • The IL-6 antagonists are thought to limit lung damage because blocking IL-6 lowers inflammation and prevents cytokine storm in COVID-19 infections.

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.